ALERE INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-12-13: Form 8-K; Period of report 2016-12-08; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
- 2016-11-04: Form 8-K; Period of report 2016-11-04; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2016-10-24: Form 8-K; Period of report 2016-10-21; Description 5.07 Submission of Matters to a Vote of Security Holders; 5.08 Shareholder Director Nominations; 8.01 Other Events; Details 5.07.
- 2016-09-06: Form 8-K; Period of report 2016-09-06; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-12-13 | 8-K | 2016-12-08 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Alere Inc. (“Company”) held its 2016 Annual Meeting of Stockholders (“2016 Annual Meeting”) on December 8, 2016. | d297915d8k.htm |
| 2016-11-04 | 8-K | 2016-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2016, Alere Inc. (the “Company” or “Alere”) issued a press release announcing our financial results for the fiscal quarter ended September 30, 2016. | d59384d8k.htm |
| 2016-10-24 | 8-K | 2016-10-21 | 5.07 Submission of Matters to a Vote of Security Holders; 5.08 Shareholder Director Nominations; 8.01 Other Events | 5.07 On October 21, 2016, Alere Inc. (the “Company”) held a special meeting of holders of shares of the Company’s common stock (the “Special Meeting”). 5.08 To the extent applicable, the information in the second and third paragraphs of Item 8.01 of this Form 8-K is incorporated by reference into this Item 5.08. 8.01 On October 21, 2016, the Company issued a press release announcing the results of the stockholder vote at the Special Meeting. | form8k.htm |
| 2016-09-06 | 8-K | 2016-09-06 | 2.02 Results of Operations and Financial Condition | 2.02 On September 6, 2016, Alere Inc. (the “Company” or “Alere”) issued a press release announcing our financial results for the fiscal quarter ended June 30, 2016. | form8k.htm |
| 2016-08-18 | 8-K | 2016-08-18 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | form8-k.htm |
| 2016-08-17 | 8-K/A | 2016-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 Attached as Exhibit 99.1 to the original Form 8-K filed on August 8, 2016 was a copy of a press release of Alere Inc. dated August 8, 2016, announcing the Company’s financial results for both the fiscal quarter and fiscal year ended December 31, 2015, which was furnished to the Securities and Exchange Commission. | d265054d8ka.htm |
| 2016-08-17 | 8-K | 2016-08-17 | 2.02 Results of Operations and Financial Condition | 2.02 On August 17, 2016, Alere Inc. (the “Company” or “Alere”) issued a press release announcing our financial results for the fiscal quarter ended March 31, 2016. | d209854d8k.htm |
| 2016-08-10 | 8-K | 2016-08-10 | 8.01 Other Events | 8.01 On August 10, 2016, Alere Inc. (the “Company” or “Alere”) filed Form 12b-25 disclosing that the Company would be unable to file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2016 (the “Second Quarter Quarterly Report”) within the prescribed time period without unreasonable effort or expense. | form8-k.htm |
| 2016-08-08 | 8-K | 2016-08-08 | 2.02 Results of Operations and Financial Condition; 2.06 Material Impairments | 2.02 On August 8, 2016, Alere Inc. (the “Company” or “Alere”) issued a press release announcing our financial results for both the fiscal quarter and fiscal year ended December 31, 2015. 2.06 On July 12, 2016, the Company filed a Current Report on Form 8-K disclosing that, following a collaborative process with the U.S. Food and Drug Administration, the Company would be initiating a voluntary withdrawal of the Alere INRatio® and INRatio®2 PT/INR Monitoring System and that, at that time, Alere expected to record approximately $70 — $90 million of related charges in 2016 relating to this voluntary withdrawal in the United States and related action outside the U.S. On August 8, 2016, the Company filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (the “2015 Annual Report”). | form8k.htm |
| 2016-07-14 | 8-K | 2016-07-14 | 2.02 Results of Operations and Financial Condition | 2.02 On July 14, 2016, Alere Inc. (the “Company” or “Alere”) issued a press release announcing certain preliminary unaudited financial results for the fiscal year ended December 31, 2015 and the quarter ended March 31, 2016. | form8k.htm |
| 2016-07-12 | 8-K | 2016-07-11 | 2.06 Material Impairments | 2.06 On July 11, 2016, Alere Inc. (the “Company”) issued a press release announcing that, following a collaborative process with the U.S. Food and Drug Administration, the Company will be initiating a voluntary withdrawal of the Alere INRatio® and INRatio®2 PT/INR Monitoring System. | d225623d8k.htm |
| 2016-05-10 | 8-K | 2016-05-10 | 8.01 Other Events | 8.01 On April 29, 2016, Alere Inc. (the “Company”) commenced consent solicitations relating to the Company’s 6.500% Senior Subordinated Notes due 2020, 6.375% Senior Subordinated Notes due 2023 and 7.250% Senior Notes due 2018 (collectively, the “Notes”). | form8k.htm |
| 2016-04-28 | 8-K | 2016-04-22 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | form8k.htm |
| 2016-04-19 | 8-K | 2016-04-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 3, 2015, Alere Inc. (the “Company”) filed a current report on Form 8-K announcing that Carla Flakne would retire from her position as Chief Accounting Officer of the Company effective as of March 31, 2016. | form8k.htm |
| 2016-04-04 | 8-K | 2016-04-04 | 8.01 Other Events | 8.01 Alere Inc., a Delaware corporation (“Alere” or the “Company”), has determined that it no longer plans to divest its stake in Swiss Precision Diagnostics (“SPD”), a 50/50 joint venture with Procter & Gamble Company for the development, manufacture, marketing and sale of consumer diagnostic products including over-the-counter pregnancy and fertility and ovulation tests. | form8k.htm |
| 2016-03-21 | 8-K | 2016-03-16 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 8.01 Other Events | 3.01 On March 16, 2016, Alere Inc. (the “Company” or “Alere”) received a notice from the New York Stock Exchange (the “NYSE”) indicating that the Company is not in compliance with the NYSE’s continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (the “2015 Form 10-K”). 8.01 Attached as Exhibit 99.1 hereto, and incorporated herein by reference, is a copy of the Company’s press release dated March 21, 2016, announcing the receipt of the NYSE notice. | form8k.htm |
| 2016-03-15 | 8-K | 2016-03-11 | 8.01 Other Events | 8.01 On February 26, 2016, Alere Inc., a Delaware corporation (“Alere” or the “Company”), filed a Form 12b-25 (the “Form 12b-25”) disclosing that the Company would be unable to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (the “2015 Form 10-K”) within the prescribed time period without unreasonable effort or expense. | form8k.htm |
| 2016-03-02 | 8-K | 2016-02-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 25, 2016, the Compensation Committee, or the Committee, of our Board of Directors made determinations regarding the salaries of our named executive officers for 2016 and the terms of our 2016 Short-Term Incentive Plan, or the 2016 STIP. | d152565d8k.htm |
| 2016-02-01 | 8-K | 2016-01-30 | 1.01 Entry into a Material Definitive Agreement; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 5.03 On January 30, 2016, the Board approved an amendment (the “Amendment”) to the Amended and Restated By-Laws of the Company (the “By-Laws”), which became effective immediately. 8.01 Attached as Exhibit 99.1 hereto, and incorporated herein by reference, is a copy of the Company’s press release dated February 1, 2016, announcing the execution of the Merger Agreement. | form8-k.htm |
| 2016-01-11 | 8-K | 2016-01-11 | 7.01 Regulation FD Disclosure | 7.01 On January 11, 2016, Alere Inc. made a presentation at the 2016 J.P. Morgan Healthcare Conference. | d118365d8k.htm |